Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.

Belanger, David B; Williams, Michael J; Curran, Patrick J; Mandal, Amit K; Meng, Zhaoyang; Rainka, Matthew P; Yu, Tao; Shih, Neng-Yang; Siddiqui, M Arshad; Liu, Ming; Tevar, Seema; Lee, Suining; Liang, Lianzhu; Gray, Kimberly; Yaremko, Bohdan; Jones, Jennifer; Smith, Elizabeth B; Prelusky, Dan B; Basso, Andrea D

Belanger, David B; Williams, Michael J; Curran, Patrick J; Mandal, Amit K; Meng, Zhaoyang; Rainka, Matthew P; Yu, Tao; Shih, Neng-Yang; Siddiqui, M Arshad; Liu, Ming; Tevar, Seema; Lee, Suining; Liang, Lianzhu; Gray, Kimberly; Yaremko, Bohdan; Jones, Jennifer; Smith, Elizabeth B; Prelusky, Dan B; Basso, Andrea D.

Affiliation

Belanger DB; Department of Medicinal Chemistry, Merck Research Laboratories, 320 Bent Street, Cambridge, MA 02141, USA. david.belanger@merck.com

Bioorg Med Chem Lett ; 20(22): 6739-43, 2010 Nov 15.

Article in En | MEDLINE | ID: mdl-20855207

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazines / Protein Serine-Threonine Kinases / Protein Kinase Inhibitors / Imidazoles Limits: Animals / Female / Humans Language: En Journal: Bioorg Med Chem Lett Journal subject: BIOQUIMICA / QUIMICA Year: 2010 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google